CareLit Fachartikel
Pioglitazone as treatment for multiple sclerosis
C Kaiser, D Skias, K Thulborn, G Katsamakis, D Shukla, D Feinstein · Aktuelle Neurologie · 2005 · Heft 10
Dokument
1163534
CareLit-ID
Jahr
2005
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Objective: To determine whether Pioglitazone (Pio), a peroxisome proliferator activated receptor gamma (PPARg) agonist, is safe in Relapsing Remitting Multiple Sclerosis (RRMS) patients and modifies T-cell activation or functional MRI activation patterns. Background: MS is a chronic autoimmune disease of the central nervous system, which mostly appears in the relapsing remitting form. Available treatments are only partially effective and have significant side effects, therefore new therapies are needed. PPARg agonists, which are FDA approved drugs for treatment of Type II diabetes mellitus, were shown to signifi…
Schlagworte
Cytokine
Blood
Diffusion Tensor Imaging
Diabetes Mellitus
Cytokines
Diffusion
Avonex
Actos
After
Aktuelle Neurologie
